BioStock: Medivir presents promising results in difficult-to-treat patient population

– We are particularly encouraged by the durable benefit, with patients remaining on treatment for much longer than expected. More than 10 months median time to progression is significantly longer than previously achieved with second-line treatment with Lenvima monotherapy or other treatment options, says Medivir's CEO Jens Lindberg.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/medivir-presents-promising-results-in-difficult-to-treat-patient-population/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Datum 2024-06-27, kl 10:00
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!